# FIGURE 3-4a. CLASSIFYING ASTHMA SEVERITY IN CHILDREN 0-4 YEARS OF AGE

 Classifying severity in children who are not currently taking long-term control medication.

Components of Severity		Classification of Asthma Severity (Children 0-4 years of age)					
			Persistent				
		Intermittent	Mild	Moderate	Severe		
	Symptoms	≤2 days/week	>2 days/week but not daily	Daily	Throughout the day		
Impairment	Nighttime awakenings	0	1-2x/month	3-4x/month	>1x/week		
	Short-acting beta <sub>2</sub> -agonist use for symptom control (not prevention of EIB)	≤2 days/week	>2 days/week but not daily	Daily	Several times per day		
	Interference with normal activity	None	Minor limitation	Some limitation	Extremely limited		
Exacerbations  Risk requiring oral		0–1/year	≥2 exacerbations in 6 months requiring oral steroids, or ≥4 wheezing episodes/1 year lasting >1 day AND risk factors for persistent asthma				
	systemic corticosteroids	Consider severity and interval since last exacerbation.  Frequency and severity may fluctuate over time.					
	Charles and	Exacerbations of any severity may occur in patients in any severity category					

# FIGURE 3-5a. ASSESSING ASTHMA CONTROL IN CHILDREN 0-4 YEARS OF AGE

Components of Control		Classification of Asthma Control (Children 0-4 years of age)				
		Well Controlled	Not Well Controlled	Very Poorly Controlled		
	Symptoms	≤2 days/week	>2 days/week	Throughout the day		
	Nighttime awakenings	1x/month	>1x/month	>1x/week		
Impairment	Interference with normal activity	None	Some limitation	Extremely limited		
	Short-acting beta <sub>2</sub> -agonist use for symptom control (not prevention of EIB)	≤2 days/week	>2 days/week	Several times per day		
	Exacerbations requiring oral systemic corticosteroids	0–1/year	2–3/year	>3/year		
Risk	Treatment-related adverse effects	Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.				

AMHTZA	CONTRO	TESTIM
MOINIM	CONTRACT	LIEGI

This survey was designed to help you describe your asthma and how your asthma affects how you feel and what you are able to do. To complete it, please mark an X in the one box that best describes your answer.

you	r answer.				
1.	In the past 4 week at work or at home		time did your asthr	na keep you from ge	tting as much done
	All of the time	Most of the time	Some of the time	A little of the time	None of the time
	_	_		•	-
	□1	□2	□3	□4	□6
2.	During the past 4	weeks, how often h	ave you had shortne	ess of breath?	
	More than		3 to 6	Once or twice	
	once a day	Once a day	times a week	a week	Not at all
	•	•	•	•	_
	□1	□2	□3	□4	□5
3.				ptoms (wheezing, co or earlier than usual i	
	4 or more	2 to 3			
	nights a week	nights a week	Once a week	Once or Twice	Not at all
	•	•	•	•	-
	□1	□2	□3	□4	□5
4.			ave you used your r ntil®, Maxair®, or Pr	escue inhaler or neb	ulizer medication
	3 or more	1 or 2	2 or 3	Orice a week	
	times per day	times per day	times per week	or less	Not at all
	•	•	•	•	_
		□2	□3	□4	□5
5.	How would you rai	te your asthma con	trol during the past	4 weeks?	
	Not Controlled	Poorly	Somewhat	Well	Completely
	at all	Controlled	Controlled	Controlled	Controlled
			-	1000	1000
				•	

My Asthma Actio	n Plan	Patient Name	
		Medical Record #:	
Physician's Name:			
	Camala	and hou	Date
Physician's Phone #: Long-Term-Control Medicines	How Much To Take	ted by:	Other Instructions
		times per day EVERY DAY!	
		times per day EVERY DAY!	
		times per day EVERY DAY!	
		times per day EVERY DAY!	
Quick-Relief Medicines	How Much To Take	How Often	Other Instructions  NOTE: If this medicine is needed
		Take ONLY as needed	frequently, call physician to consider increasing long-term-control medications.
in the GRE	EN zone.) My Personal Best Public Floor		ke my asthma worse like:
I do not feel good.  (My peak flow is in the YELL  My symptoms may incl or more of the followin  Wheeze Tight chest Cough Shortness of breat Waking up at night asthma symptoms	OW zone.)  BO% Personal Best  ude one g:	Avoid things that male CAUTION. I should co asthma medicines eve	ntinue taking my long-term-control ery day AND:
I do not feel good.  (My peak flow is in the YELL  My symptoms may incl or more of the followin  • Wheeze • Tight chest • Cough • Shortness of breat • Waking up at night asthma symptoms • Decreased ability	OW zone.)  BO% Personal Best  Bo% Personal Best	Avoid things that male CAUTION. I should consthem medicines even Take  If I still do not feel good, of Green Zone within 1 holds Increase	ntinue taking my long-term-control ery day AND:  or my peak flow is not back in the our, then I should:

Source: Adapted and reprinted with permission from the Regional Asthma Management and Prevention (RAMP) Initiative, a program of the Public Health Institute. http://www.calasthma.org/uploads/resources/actionplanpdf.pdf; San Francisco Bay Area Regional Asthma Management Plan, http://www.rampasthma.org

## FIGURE 4-1a. STEPWISE APPROACH FOR MANAGING ASTHMA IN CHILDREN 0-4 YEARS OF AGE

Intermittent Asthma

### Persistent Asthma: Daily Medication

Consult with asthma specialist if step 3 care or higher is required. Consider consultation at step 2.



Step 4

Preferred:

Medium-dose ICS + either LABA or

## Step 5 Preferred:

Step 6

High-dose ICS +

either

LABA or

Montelukast

Oral systemic

corticosteroids

Preferred:

High-dose ICS + either LABA or Montelukast

Step up if needed

(first, check adherence. inhaler technique, and environmental control)

> **Assess** control

Step down if possible

(and asthma is well controlled at least 3 months)

Step 1

Preferred: SABA PRN

## Step 2

Preferred: Low-dose ICS

Alternative:

Cromolyn or Montelukast

## Step 3

Preferred: Medium-dose

ICS

Montelukast

## Patient Education and Environmental Control at Each Step

Quick-Relief Medication for All Patients

SABA as needed for symptoms. Intensity of treatment depends on severity of symptoms.

With viral respiratory infection: SABA q 4-6 hours up to 24 hours (longer with physician consult). Consider short course of oral systemic corticosteroids if exacerbation is severe or patient has history of previous severe exacerbations.

Caution: Frequent use of SABA may indicate the need to step up treatment. See text for recommendations on initiating daily long-term-control therapy.



# FIGURE 4-2a. CLASSIFYING ASTHMA SEVERITY AND INITIATING TREATMENT IN CHILDREN 0-4 YEARS OF AGE

Assessing severity and initiating therapy in children who are not currently taking long-term control medication

Components of Severity		Classification of Asthma Severity (0-4 years of age)				
		Persistent				
		Intermittent	Mild	Moderate Severe		
	Symptoms	≤2 days/week	>2 days/week but not daily	Daily	Throughout the day	
	Nighttime awakenings	0	1–2x/month	3-4x/month	>1x/week	
Impairment	Short-acting beta <sub>2</sub> -agonist use for symptom control (not prevention of EIB)	≤2 days/week	>2 days/week but not daily	Daily	Several times per day	
	Interference with normal activity	None	Minor limitation	Some limitation	Extremely limited	
Risk	Exacerbations	$\ge 2$ exacerbations in 6 months requiring oral systemic corticosteroids, or $\ge 4$ wheezing episodes/1 year lasting $> 1$ day AND risk factors for persistent asthma				
KISK	requiring oral systemic corticosteroids	Fre	val since last exacer may fluctuate over t ur in patients in any	time.		
Recommended Step for Initiating Therapy  (See figure 4–1a for treatment steps.)		Step 1	Step 2 Step 3 and consider short course of oral systemic corticosteroids			
		In 2–6 weeks, depending on severity, evaluate level of asthma control that is achieved. If no clear benefit is observed in 4–6 weeks, consider adjusting therapy or alternative diagnoses.				

# FIGURE 4-3a. ASSESSING ASTHMA CONTROL AND ADJUSTING THERAPY IN CHILDREN 0-4 YEARS OF AGE

		Classification	of Asthma Contro	ol (0-4 years of age)			
Components of Control		Well Controlled	Not Well Controlled	Very Poorly Controlled			
	Symptoms	≤2 days/week	>2 days/week	Throughout the day			
Impairment	Nighttime awakenings	≤1x/month	>1x/month	>1x/week			
	Interference with normal activity	None	Some limitation	Extremely limited			
	Short-acting beta <sub>2</sub> -agonist use for symptom control (not prevention of EIB)	≤2 days/week	>2 days/week	Several times per day			
	Exacerbations requiring oral systemic corticosteroids	0–1/year	2–3/year	>3/year			
Risk	Treatment-related adverse effects	Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk,					
Recommended Action for Treatment  (See figure 4–1a for treatment steps.)		<ul> <li>Maintain current treatment.</li> <li>Regular followup every 1–6 months.</li> <li>Consider step down if well controlled for at least 3 months.</li> </ul>	<ul> <li>Step up (1 step) and</li> <li>Reevaluate in 2–6 weeks.</li> <li>If no clear benefit in 4–6 weeks, consider alternative diagnoses or adjusting therapy.</li> <li>For side effects, consider alternative treatment options.</li> </ul>	<ul> <li>Consider short course of oral systemic corticosteroids,</li> <li>Step up (1–2 steps), and</li> <li>Reevaluate in 2 weeks.</li> <li>If no clear benefit in 4–6 weeks, consider alternative diagnoses or adjusting therapy.</li> <li>For side effects, consider alternative treatment options.</li> </ul>			